ZA201306735B - Dosing regimens for the treatment of fabry disease - Google Patents

Dosing regimens for the treatment of fabry disease

Info

Publication number
ZA201306735B
ZA201306735B ZA2013/06735A ZA201306735A ZA201306735B ZA 201306735 B ZA201306735 B ZA 201306735B ZA 2013/06735 A ZA2013/06735 A ZA 2013/06735A ZA 201306735 A ZA201306735 A ZA 201306735A ZA 201306735 B ZA201306735 B ZA 201306735B
Authority
ZA
South Africa
Prior art keywords
treatment
dosing regimens
fabry disease
fabry
disease
Prior art date
Application number
ZA2013/06735A
Other languages
English (en)
Inventor
Douglas Stuart Greene
Kenneth Joseph Valenzano
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46831259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201306735(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of ZA201306735B publication Critical patent/ZA201306735B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01062—Glycosylceramidase (3.2.1.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
ZA2013/06735A 2011-03-11 2013-09-09 Dosing regimens for the treatment of fabry disease ZA201306735B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161451798P 2011-03-11 2011-03-11
US201161578201P 2011-12-20 2011-12-20
US201261596165P 2012-02-07 2012-02-07
PCT/US2012/028260 WO2012125402A2 (en) 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease

Publications (1)

Publication Number Publication Date
ZA201306735B true ZA201306735B (en) 2014-07-30

Family

ID=46831259

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/06735A ZA201306735B (en) 2011-03-11 2013-09-09 Dosing regimens for the treatment of fabry disease

Country Status (16)

Country Link
US (4) US20140219986A1 (cg-RX-API-DMAC7.html)
EP (2) EP2683382B1 (cg-RX-API-DMAC7.html)
JP (5) JP2014528901A (cg-RX-API-DMAC7.html)
KR (1) KR20140011367A (cg-RX-API-DMAC7.html)
CN (2) CN107088225A (cg-RX-API-DMAC7.html)
AU (6) AU2012229330B2 (cg-RX-API-DMAC7.html)
CA (1) CA2829947C (cg-RX-API-DMAC7.html)
CL (1) CL2013002601A1 (cg-RX-API-DMAC7.html)
EA (1) EA031874B1 (cg-RX-API-DMAC7.html)
ES (1) ES2807502T3 (cg-RX-API-DMAC7.html)
HK (1) HK1242998A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013010446A (cg-RX-API-DMAC7.html)
SG (2) SG10201604757RA (cg-RX-API-DMAC7.html)
TW (3) TW201740945A (cg-RX-API-DMAC7.html)
WO (1) WO2012125402A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306735B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2533050T6 (da) 2006-05-16 2015-09-21 Amicus Therapeutics Inc Behandlingsmuligheder ved Fabrys sygdom
HUE042882T2 (hu) 2008-02-12 2019-07-29 Amicus Therapeutics Inc Eljárás betegségek farmakológiai chaperonnal történõ kezelésére adott válasz elõrejelzésére
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014164534A2 (en) 2013-03-11 2014-10-09 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
CN106687596A (zh) * 2014-02-17 2017-05-17 葛兰素史密斯克莱知识产权发展有限公司 微生物学方法
RS64072B1 (sr) 2014-03-19 2023-04-28 Genzyme Corp Mesto-specifični glikoinženjering ciljnih delova
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP7001593B2 (ja) 2015-08-11 2022-01-19 コグノア， インコーポレイテッド 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
EP3432882B1 (en) * 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
KR20240017126A (ko) * 2016-07-19 2024-02-06 아미쿠스 세라퓨틱스, 인코포레이티드 Ert-치료경험이 없는 환자 및 있는 환자에서 파브리병의 치료
WO2018090009A1 (en) 2016-11-14 2018-05-17 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
JP7324709B2 (ja) * 2017-02-09 2023-08-10 コグノア，インク． デジタル個別化医療のためのプラットフォームとシステム
HUE069837T2 (hu) * 2017-05-30 2025-04-28 Amicus Therapeutics Inc Bizonyos mutációkat hordozó Fabry-kóros betegek kezelése
BR112019025083B1 (pt) 2017-05-30 2022-08-09 Amicus Therapeutics, Inc Métodos de tratamento de pacientes portadores de fabry com insuficiência renal
JP7066157B2 (ja) 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
EP3749307B1 (en) * 2018-02-06 2025-12-10 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4299117A3 (en) * 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
AU2020248351B2 (en) 2019-03-22 2025-09-25 Cognoa, Inc. Personalized digital therapy methods and devices
CN113939534B (zh) 2019-04-03 2025-02-28 建新公司 具有降低的断裂的抗αβTCR结合多肽
EA202290024A1 (ru) * 2019-06-11 2022-03-14 Амикус Терапьютикс, Инк. Способы лечения болезни фабри у пациентов с почечной недостаточностью
CA3147055A1 (en) 2019-08-07 2021-02-11 Elfrida Benjamin Methods of treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20240197706A1 (en) * 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551177A (en) * 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ES2686775T3 (es) * 2003-01-31 2018-10-19 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CN100457106C (zh) * 2005-06-15 2009-02-04 同济大学 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用
DK2533050T6 (da) * 2006-05-16 2015-09-21 Amicus Therapeutics Inc Behandlingsmuligheder ved Fabrys sygdom
US20100113517A1 (en) * 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
US9056101B2 (en) * 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US20100291060A1 (en) * 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a

Also Published As

Publication number Publication date
EP2683382B1 (en) 2020-04-22
AU2020201715A1 (en) 2020-04-09
AU2012229330B2 (en) 2016-04-21
CA2829947A1 (en) 2012-09-20
MX2013010446A (es) 2014-03-27
KR20140011367A (ko) 2014-01-28
NZ615726A (en) 2015-01-30
US20140219986A1 (en) 2014-08-07
JP2023093448A (ja) 2023-07-04
CN103974619B (zh) 2017-02-15
CL2013002601A1 (es) 2014-03-28
TW201302197A (zh) 2013-01-16
US20240115708A1 (en) 2024-04-11
EP2683382A2 (en) 2014-01-15
JP2014528901A (ja) 2014-10-30
WO2012125402A2 (en) 2012-09-20
AU2022203011A1 (en) 2022-05-26
AU2012229330A1 (en) 2013-10-03
HK1242998A1 (zh) 2018-07-06
TWI624258B (zh) 2018-05-21
US20180153999A1 (en) 2018-06-07
EP2683382A4 (en) 2014-10-22
CN103974619A (zh) 2014-08-06
AU2016204445A1 (en) 2016-07-21
AU2018201637A1 (en) 2018-04-05
EA031874B1 (ru) 2019-03-29
JP2020033360A (ja) 2020-03-05
TW201634048A (zh) 2016-10-01
TWI624259B (zh) 2018-05-21
WO2012125402A3 (en) 2014-05-01
JP2021098697A (ja) 2021-07-01
AU2024205251A1 (en) 2024-08-22
ES2807502T3 (es) 2021-02-23
TW201740945A (zh) 2017-12-01
SG193379A1 (en) 2013-10-30
CN107088225A (zh) 2017-08-25
EA201301018A1 (ru) 2014-04-30
US20200268890A1 (en) 2020-08-27
EP3698792A1 (en) 2020-08-26
AU2016204445B2 (en) 2018-03-22
JP2017132780A (ja) 2017-08-03
SG10201604757RA (en) 2016-08-30
CA2829947C (en) 2019-01-15

Similar Documents

Publication Publication Date Title
ZA201306735B (en) Dosing regimens for the treatment of fabry disease
SI2844279T1 (sl) Dozirni režimi za zdravljenje Pompejeve bolezni
ZA201403795B (en) Formulations for the treatment of diabetes
IL229254A0 (en) Therapeutic antibodies
EP2776441A4 (en) TREATMENT METHOD WITH MULTIPLE PHARMACEUTICAL AGENTS
GB201114212D0 (en) Therapeutic agents
GB201119401D0 (en) Therapeutic agents
EP2704712A4 (en) ISOXAZOLINES AS THERAPEUTIC AGENTS
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
EP2700429A4 (en) DRUG SOLUTION APPLICATOR
ZA201307760B (en) Treatment regimens
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
ZA201308176B (en) Therapeutic treatment
HK1192488A (zh) 用作治疗法布瑞氏症的给药方案
GB201106981D0 (en) Compounds for the treatment of clostridium difficle-associated disease
IL232294B (en) Preparations for the treatment of diabetes
GB201110895D0 (en) Therapeutic use
GB201117026D0 (en) Non-invasive monitor
GB201110614D0 (en) Therapeutic agents
GB201101128D0 (en) Therapeutic agents
GB201115558D0 (en) Therapeutic agents
ZA201308992B (en) Therapeutic antibodies
GB201104632D0 (en) Use of medicament